hepatotoxicity. Toxic liver disease with hepatic necrosis, with coma
Conditions
Interventions
Intervention 1: Intervention group: Livergol 140 mg three tablets daily after meals (produced by Goldaroo company), oral, for 4 weeks. Intervention 2: Control group: Placebo tablets for Livergol, thre
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age between 18-65 y Patients with diagnosis of non-metastatic breast cancer who will be treated by doxurobicin after mastectomy Signing the written consent
Exclusion criteria
Exclusion criteria: Viral hepatitis History of hypersensitivity to silymarin or similar compounds Pregnancy and lactation Liver involvement grade 2 or higher based on ultrasound evaluation Any kind of liver injury resulting in rise of liver enzymes or bilirubin to higher than upper limit normal Hepatobiliary obstruction Renal failure (GFR<30 mL/min) Malabsorption syndrome Concomitant use of heptotoxic agents or antioxidants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of hepatic transaminases, total billirubin, direct billirubin, prothrombin time, serum albumin, alkalin phosphatase. Timepoint: At the beginning of the study, 2 weeks after the beginning of study, one month after the beginning of the study. Method of measurement: Serum level measurement by the laboratory.;Liver ultrasound to determine the stage of the fatty liver. Timepoint: At the beginning of the study, one month after the beginning of the study. Method of measurement: Ultrasound evaluation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum level of creatinine and urea. Timepoint: At the beginning of the study, 2 weeks after the beginning of study, one month after the beginning of the study. Method of measurement: Serum level measurement by the laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSepideh Elyasi
Mashhad University of Medical Sciences
Outcome results
None listed